Detalhe da pesquisa
1.
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
Hepatology
; 61(4): 1127-35, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25614962
2.
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
JAMA
; 313(17): 1728-35, 2015 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25942723
3.
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
Lancet Gastroenterol Hepatol
; 8(2): 120-132, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521501
4.
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
Lancet Gastroenterol Hepatol
; 5(10): 918-926, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32531259
5.
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
J Med Virol
; 80(9): 1576-80, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18649339
6.
Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis.
Ann Hepatol
; 7(1): 72-7, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18376370